Unternehmensübersicht
Ginkgo Bioworks Holdings, Inc. operates primarily within the healthcare sector, specifically targeting the biotechnology industry by developing a specialized platform for cell engineering in the United States. The company executes its operational strategy through two distinct segments, namely Cell Engineering and Biosecurity, offering comprehensive research and development solutions alongside proprietary cell engineering tools to its clientele. In terms of corporate scale, the entity maintains a market capitalization of $367.21 million while generating annual revenue of $170.16 million with a workforce consisting of 485 employees. These financial metrics indicate that the company functions as a mid-sized biotechnology entity, where the current market cap suggests a valuation that is significantly detached from its trailing twelve-month revenue base, reflecting the high-risk profile often associated with early-stage biotech firms that prioritize research infrastructure over immediate profitability.
Finanzielle Gesundheit
The company reported a revenue of $170.16 million over the trailing twelve months, yet this figure masks a substantial net loss of $-312,763,008, resulting in an EBITDA of $-267,822,000. The significant disparity between the $170.16 million in revenue and the $-312.76 million in net income reveals a highly expansive cost structure characterized by heavy operational expenses that outpace top-line generation, a common trait in capital-intensive biotechnology research and development phases. Furthermore, the firm recorded a free cash flow of $-72,883,000, which indicates a consistent outflow of cash resources that constrains current financial flexibility and necessitates continuous access to external capital markets to fund operations. The margin analysis presents a gross margin of 72.4%, suggesting effective cost control relative to sales, but this is offset by an operating margin of -209.7% and a profit margin of -183.8%, both of which signal severe structural inefficiencies or massive overhead burdens relative to the revenue generated. Regarding liquidity and leverage, the company holds $422.62 million in cash against $439.88 million in debt, resulting in a debt-to-equity ratio of 86.49 that characterizes a highly leveraged balance sheet approaching insolvency thresholds without additional equity financing. Despite the high leverage, the current ratio stands at 4.92, which theoretically indicates strong short-term liquidity positions capable of covering immediate obligations, though this may be artificially inflated by the inclusion of non-cash items or long-term debt classified as current liabilities. Additionally, the return on equity is -51.1% and the return on assets is -15.4%, metrics that collectively reveal that management effectiveness in generating value for shareholders and utilizing asset bases is currently negative due to persistent operating losses.
Bewertungsanalyse
Valuation metrics for Ginkgo Bioworks present a complex picture due to the absence of earnings, as the P/E ratio (TTM) is N/A and the forward P/E is listed at -1.63. The negative forward P/E implies that the market is not valuing the company based on current or near-term earnings power, but rather on future growth expectations or potential turnaround scenarios that are not yet realized in financial statements. The price-to-book ratio of 0.68 indicates that the market is currently pricing the company at a discount to its book value, suggesting that investors perceive significant risks that outweigh the tangible assets recorded on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 2.16 and the EV/EBITDA of -1.35 further illustrate that the company is being valued on revenue multiples rather than profitability, a standard practice for unprofitable biotechs but one that carries substantial downside risk if revenue targets are missed. In terms of price volatility, the stock has traded within a 52-week range between a high of $17.58 and a low of $5.00. Without a specific current price provided in the available facts to calculate a precise percentage, the stock's position relative to this range remains indeterminate based solely on the provided dataset, though the wide spread suggests high sensitivity to market sentiment. The beta value of 1.59 confirms that the stock exhibits price volatility that is significantly higher than the broader market, making it a high-risk investment suitable only for portfolios with a high tolerance for equity fluctuations.
Growth & Income
Revenue growth year-over-year stands at -23.8%, while earnings growth is N/A due to the company's lack of profitability over the trailing period. The absence of positive earnings growth is inherent to the current financial state, as the company has not yet reached a stage where earnings are growing faster than revenue or vice versa due to the existence of net losses. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, indicating that all available cash flows are theoretically directed toward reinvesting into growth initiatives, research, and debt servicing rather than returning capital to shareholders. This reinvestment strategy is typical for biotechnology firms attempting to bridge the gap between cash burn and commercial product launch, though the current negative free cash flow limits the scope of such internal reinvestment. The overall growth and income profile is characterized by negative revenue expansion and zero dividend income, reflecting a business model that relies on external capital injections to sustain operations and fund future development milestones rather than generating organic shareholder value through dividends or earnings growth.